ClinicalTrials.gg
CompletedNCT01332253Updated Nov 3, 2016Results posted

Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy

A Phase 3 interventional study of Intravenous ibuprofen and Normal Saline in Tonsillectomy, sponsored by Cumberland Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-11-03.

Sponsored by Cumberland Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Study summary

The hypothesis is that a single, pre-operative dose of intravenous ibuprofen will significantly reduce post-operative fentanyl use compared to placebo.

02

Conditions studied

  • Tonsillectomy

Keywords

  • Tonsillectomy, Pediatric
03

In context

Lead sponsor

Cumberland Pharmaceuticals is the lead sponsor of 49 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients between 6 and 17 years of age scheduled to undergo tonsillectomy.

Exclusion criteria

Exclusion Criteria:

  1. Have inadequate intravenous access
  2. Patients with significant cognitive impairment
  3. Active, asthma
  4. History of allergy or to any component of intravenous ibuprofen, NSAIDs, aspirin (or related products), cyclooxygenase-2 inhibitors, or fentanyl.
  5. Have a history of congenital bleeding diathesis (e.g. hemophilia) or any active clinically significant bleeding
  6. Any child with obstructive sleep apnea, defined as an Apnea-Hypopnea Index of greater than or equal to 5.0
  7. Have taken drugs within 30 days before clinical trial material administration.
  8. Inability to understand the requirements of the study or be unwilling to provide written (as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB]) and agree to abide by the study restrictions. Surrogates will be needed for most patients.
  9. Refusal to provide written authorization for use and disclosure of protected health information.
  10. Be otherwise unsuitable for the study, in the opinion of the Investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Intravenous Ibuprofen

    Drug: Intravenous ibuprofen

  • Placebo comparator
    Normal Saline

    Other: Normal Saline

Interventions

  • Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.

  • OtherNormal Saline

    Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.

06

What researchers measure

Primary outcomes

  1. Number of Doses of Fentanyl Administered in the Postoperative Period Prior to Discharge.

    To evaluate the primary objective of reduced fentanyl use in the post-operative period, the number of fentanyl doses (0.5 mcg/kg IV) administered in the post-operative period prior to discharge will be measured.

    Time frame: 4 hours

Secondary outcomes

  1. Postoperative Pain as Measured by the Visual Analog Scale (VAS) 30 Minutes Post-procedure.

    The patient's self-reported pain at 30 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.

    Time frame: 30 minutes post-procedure

  2. Postoperative Pain as Measured by the Visual Analog Scale (VAS) 60 Minutes Post-procedure.

    To evaluate the secondary objective of pain, the patient's self-reported pain at 60 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.

    Time frame: 60 minutes post-procedure

  3. Postoperative Pain as Measured by the Visual Analog Scale (VAS) 90 Minutes Post-procedure.

    o evaluate the secondary objective of pain, the patient's self-reported pain at 90 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.

    Time frame: 90 minutes post-procedure

  4. Postoperative Pain as Measured by the Visual Analog Scale (VAS) 120 Minutes Post-procedure.

    To evaluate the secondary objective of pain, the patient's self-reported pain at 120 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.

    Time frame: 120 minutes post-procedure

  5. Time to Discharge Post Procedure.

    To evaluate the secondary objective of pain, the time to participant discharge will be measured.

    Time frame: Discharge

  6. Time to Swallow Post Procedure.

    Swallowing will be assessed every 15 minutes following arrival to the recovery room; the time to first swallow will be recorded.

    Time frame: every 15 minutes until able to swallow

  7. Parent Satisfaction With Regards to Pain Management Post Procedure.

    To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to pain management. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 1 asked "How satisfied were you with your child's pain management at the time of discharge?"

    Time frame: Discharge

  8. Parent Satisfaction With Regards to Nausea Management Post Procedure.

    To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to nausea management. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 2 asked "How satisfied were you with your child's nausea management during the study?"

    Time frame: Discharge

  9. Parental Satisfaction With Vomiting Control in the Post-Operative Period.

    To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to vomiting control. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 3 asked "How satisfied were you with your child's vomiting management during the study?"

    Time frame: Discharge

  10. Blood Loss During Surgery

    Amount of Blood Lost During Surgery in milliliters

    Time frame: End of Surgery

07

Results

Posted Nov 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneIntravenous IbuprofenNormal Saline
Started8279
Completed8279
Not completed00

Outcome measures

PrimaryNumber of Doses of Fentanyl Administered in the Postoperative Period Prior to Discharge.

To evaluate the primary objective of reduced fentanyl use in the post-operative period, the number of fentanyl doses (0.5 mcg/kg IV) administered in the post-operative period prior to discharge will be measured.

Time frame:
4 hours
Reported as:
Mean · fentanyl doses
Number of Doses of Fentanyl Administered in the Postoperative Period Prior to Discharge.
fentanyl dosesIntravenous IbuprofenNormal Saline
Number of Doses of Fentanyl Administered in the Postoperative Period Prior to Discharge.1.5 ± 1.321.7 ± 1.12
SecondaryPostoperative Pain as Measured by the Visual Analog Scale (VAS) 30 Minutes Post-procedure.

The patient's self-reported pain at 30 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.

Time frame:
30 minutes post-procedure
Reported as:
Mean · millimeters
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 30 Minutes Post-procedure.
millimetersIntravenous IbuprofenNormal Saline
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 30 Minutes Post-procedure.51 ± 30.955 ± 27.4
SecondaryPostoperative Pain as Measured by the Visual Analog Scale (VAS) 60 Minutes Post-procedure.

To evaluate the secondary objective of pain, the patient's self-reported pain at 60 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.

Time frame:
60 minutes post-procedure
Reported as:
Mean · millimeters
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 60 Minutes Post-procedure.
millimetersIntravenous IbuprofenNormal Saline
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 60 Minutes Post-procedure.39 ± 27.447 ± 30.8
SecondaryPostoperative Pain as Measured by the Visual Analog Scale (VAS) 90 Minutes Post-procedure.

o evaluate the secondary objective of pain, the patient's self-reported pain at 90 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.

Time frame:
90 minutes post-procedure
Reported as:
Mean · millimeters
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 90 Minutes Post-procedure.
millimetersIntravenous IbuprofenNormal Saline
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 90 Minutes Post-procedure.29 ± 29.335 ± 30.8
SecondaryPostoperative Pain as Measured by the Visual Analog Scale (VAS) 120 Minutes Post-procedure.

To evaluate the secondary objective of pain, the patient's self-reported pain at 120 minutes post-procedure will be measured using a VAS scale. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. A lower score represents less pain while a higher score represents more pain.

Time frame:
120 minutes post-procedure
Reported as:
Mean · millimeters
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 120 Minutes Post-procedure.
millimetersIntravenous IbuprofenNormal Saline
Postoperative Pain as Measured by the Visual Analog Scale (VAS) 120 Minutes Post-procedure.22 ± 26.227 ± 29.3
SecondaryTime to Discharge Post Procedure.

To evaluate the secondary objective of pain, the time to participant discharge will be measured.

Time frame:
Discharge
Reported as:
Mean · hours
Time to Discharge Post Procedure.
hoursIntravenous IbuprofenNormal Saline
Time to Discharge Post Procedure.1.9 ± 0.101.9 ± 0.11
SecondaryTime to Swallow Post Procedure.

Swallowing will be assessed every 15 minutes following arrival to the recovery room; the time to first swallow will be recorded.

Time frame:
every 15 minutes until able to swallow
Reported as:
Mean · hours
Time to Swallow Post Procedure.
hoursIntravenous IbuprofenNormal Saline
Time to Swallow Post Procedure.0.5 ± 0.040.4 ± 0.03
SecondaryParent Satisfaction With Regards to Pain Management Post Procedure.

To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to pain management. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 1 asked "How satisfied were you with your child's pain management at the time of discharge?"

Time frame:
Discharge
Reported as:
Number · participants
Parent Satisfaction With Regards to Pain Management Post Procedure.
participantsIntravenous IbuprofenNormal Saline
Strongly Agree5858
Agree116
Neutral11
Disagree20
Strongly Disagree00
Survey question not completed10
SecondaryParent Satisfaction With Regards to Nausea Management Post Procedure.

To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to nausea management. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 2 asked "How satisfied were you with your child's nausea management during the study?"

Time frame:
Discharge
Reported as:
Number · participants
Parent Satisfaction With Regards to Nausea Management Post Procedure.
participantsIntravenous IbuprofenNormal Saline
Strongly Agree6457
Agree75
Neutral02
Disagree00
Strongly Disagree00
Survey question not completed21
SecondaryParental Satisfaction With Vomiting Control in the Post-Operative Period.

To evaluate the secondary objective of pain, parental satisfaction during the post-operative period will be measured with regards to vomiting control. The Parental Satisfaction Survey asked the parent to base their response on their child's management from the time they arrive in the recovery room until they were discharged. Question 3 asked "How satisfied were you with your child's vomiting management during the study?"

Time frame:
Discharge
Reported as:
Number · participants
Parental Satisfaction With Vomiting Control in the Post-Operative Period.
participantsIntravenous IbuprofenNormal Saline
Strongly Agree6659
Agree34
Neutral12
Disagree00
Strongly Disagree00
Survey question not completed30
SecondaryBlood Loss During Surgery

Amount of Blood Lost During Surgery in milliliters

Time frame:
End of Surgery
Reported as:
Mean · milliliters
Blood Loss During Surgery
millilitersIntravenous IbuprofenNormal Saline
Blood Loss During Surgery15 ± 29.616 ± 39.3

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous Ibuprofen—1/82 (1.2%)7/82 (8.5%)
Normal Saline—0/79 (0%)10/79 (12.7%)
Most frequent serious events
Most frequent serious events
EventIntravenous IbuprofenNormal Saline
Tonsillar haemorrhageRespiratory, thoracic and mediastinal disorders1/820/79
Most frequent other events
Most frequent other events
EventIntravenous IbuprofenNormal Saline
AgitationNervous system disorders1/823/79
VomitingGastrointestinal disorders3/822/79
Infusion Site PainInjury, poisoning and procedural complications3/820/79
RestlessnessNervous system disorders0/822/79
Rash ErythematousSkin and subcutaneous tissue disorders0/822/79
BronchospasmImmune system disorders0/822/79

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intravenous IbuprofenNormal SalineTotal
Mean10 ± 3.49 ± 3.09 ± 3.2
Sex: Female, Male
Sex: Female, Male(Participants)Intravenous IbuprofenNormal SalineTotal
Female313162
Male514899
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intravenous IbuprofenNormal SalineTotal
Hispanic or Latino141327
Not Hispanic or Latino6866134
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intravenous IbuprofenNormal SalineTotal
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American81018
White6968137
More than one race000
Unknown or Not Reported213
Region of Enrollment
Region of Enrollment(participants)Intravenous IbuprofenNormal SalineTotal
United States8279161
08

Study locations

6 sites
  • Advanced ENT & Allergy
    Louisville, Kentucky 40207, United States
  • University Hospital, University of Medicine and Dentistry NJ
    Newark, New Jersey 07101, United States
  • Southeastern Clinical Research Associates
    Charlotte, North Carolina 28210, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Comprehensive Pain Specialists
    Hendersonville, Tennessee 37075, United States
  • Baylor College of Medicine/Texas Children's Hospital
    Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Jul 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 4 years 4 months after primary completion. A results delay was requested in Feb 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2011
First posted
Apr 11, 2011
Start
Jul 2011
Primary completionActual
Jul 2012
CompletionActual
Aug 2012
Results delay requested
Feb 3, 2014
Results first posted
Nov 3, 2016
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01332253
Responsible party
Sponsor
First posted
Apr 11, 2011
Start date
Jul 2011
Primary completion
Jul 2012
Completion
Aug 2012
Results posted
Nov 3, 2016
Last update
Nov 3, 2016

Study contacts

Art P Wheeler, MD
study director · Cumberland Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion